Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
- 30 April 2011
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 16 (7-8), 325-331
- https://doi.org/10.1016/j.drudis.2011.02.008
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- The dual PI3K/mTOR inhibitor PI‐103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib‐treated melanoma cellsInternational Journal of Cancer, 2010
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- mTOR mediated anti-cancer drug discoveryDrug Discovery Today: Therapeutic Strategies, 2009
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of RapamycinCancer Research, 2009
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Molecular Cancer Therapeutics, 2009
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)Biochemical Journal, 2009
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1Published by Elsevier BV ,2009
- Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapyMolecular Cancer Therapeutics, 2009
- Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinasesNature Chemical Biology, 2008
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006